Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ABUS

Stock Name	Arbutus Biopharma Corp
Ticker	ABUS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	CA03879J1003

Show aggregate ABUS holdings

News associated with ABUS

Wall Street Zen Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Hold: Wall Street Zen cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning. Separately, Chardan Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Monday, August 11th. […] - 2025-09-08 02:54:58
Arbutus Biopharma Corp. Q2 Earnings Summary: (RTTNews) - Below are the earnings highlights for Arbutus Biopharma Corp. (ABUS): - 2025-08-06 08:49:24
10,000 Shares in Arbutus Biopharma Corporation (NASDAQ:ABUS) Bought by Cyndeo Wealth Partners LLC: Cyndeo Wealth Partners LLC bought a new position in Arbutus Biopharma Corporation (NASDAQ:ABUS – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $35,000. Other hedge funds and other institutional investors have also […] - 2025-06-18 05:50:55
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by Wellington Management Group LLP: Wellington Management Group LLP grew its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 513,302 shares of the biopharmaceutical company’s stock after acquiring an additional 16,484 shares during the period. Wellington Management Group LLP’s holdings in Arbutus Biopharma were worth $1,678,000 […] - 2025-06-06 05:38:53
Millennium Management LLC Grows Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS): Millennium Management LLC boosted its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 36.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 343,028 shares of the biopharmaceutical company’s stock after buying an additional 92,068 shares during the quarter. Millennium Management LLC’s […] - 2025-06-05 04:24:59
ProShare Advisors LLC Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS): ProShare Advisors LLC increased its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 29.3% in the fourth quarter, HoldingsChannel reports. The firm owned 50,121 shares of the biopharmaceutical company’s stock after purchasing an additional 11,359 shares during the quarter. ProShare Advisors LLC’s holdings in Arbutus Biopharma were worth $164,000 as of its most […] - 2025-06-02 05:03:00
Deutsche Bank AG Increases Stake in Arbutus Biopharma Co. (NASDAQ:ABUS): Deutsche Bank AG increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 77.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 171,766 shares of the biopharmaceutical company’s stock after acquiring an additional 75,212 shares during the quarter. Deutsche Bank AG’s holdings in Arbutus Biopharma were worth $562,000 at the end of […] - 2025-05-29 04:44:55
Northern Trust Corp Has $4.35 Million Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS): Northern Trust Corp increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,330,683 shares of the biopharmaceutical company’s stock after acquiring an additional 102,241 shares during the period. Northern Trust Corp’s holdings in Arbutus Biopharma were worth $4,351,000 at the end of […] - 2025-05-22 04:22:55
Invesco Ltd. Purchases 3,780 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): Invesco Ltd. grew its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 5.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,831 shares of the biopharmaceutical company’s stock after buying an additional 3,780 shares during the period. Invesco Ltd.’s holdings in Arbutus Biopharma […] - 2025-05-05 04:26:47
XTX Topco Ltd Acquires 22,568 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): XTX Topco Ltd raised its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 75.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,581 shares of the biopharmaceutical company’s stock after purchasing an additional 22,568 shares during the quarter. XTX Topco Ltd’s holdings in Arbutus Biopharma were worth $172,000 at the […] - 2025-04-29 05:24:53
Rockefeller Capital Management L.P. Has $349,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS): Rockefeller Capital Management L.P. boosted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,615 shares of the biopharmaceutical company’s stock after acquiring an additional 43,615 […] - 2025-04-24 06:00:57
Arbutus Biopharma Announces Acceptance of Five Abstracts for Presentation at EASL Congress 2025: Arbutus Biopharma announces five abstracts accepted for EASL Congress 2025, focusing on hepatitis B therapies and clinical trials. - 2025-04-23 03:10:26
Bank of Montreal Can Purchases 15,567 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): Bank of Montreal Can grew its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 455,880 shares of the biopharmaceutical company’s stock after purchasing an additional 15,567 shares during the quarter. Bank of Montreal Can’s holdings in Arbutus Biopharma were worth $1,491,000 as of […] - 2025-04-18 05:06:53
25,600 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Acquired by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS acquired a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,600 shares of the biopharmaceutical company’s stock, valued at approximately $84,000. A number of […] - 2025-04-11 04:49:00
Mitsubishi UFJ Asset Management Co. Ltd. Decreases Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS): Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,660 shares of the biopharmaceutical company’s stock after selling 12,287 shares during the period. […] - 2025-04-04 05:12:59
Intech Investment Management LLC Has $187,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS): Intech Investment Management LLC increased its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 54.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,084 shares of the biopharmaceutical company’s stock after buying an additional 20,232 shares during the quarter. […] - 2025-03-28 07:12:50
Cibc World Markets Corp Takes $45,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS): Cibc World Markets Corp bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,672 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Other institutional investors and hedge funds […] - 2025-03-28 06:18:44
Arbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Growth in Short Interest: Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 8,410,000 shares, a growth of 16.6% from the February 13th total of 7,210,000 shares. Approximately 4.6% of the shares of the stock are […] - 2025-03-21 04:26:50
Arbutus Biopharma (NASDAQ:ABUS) Downgraded to “Sell” Rating by StockNews.com: StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research analysts also recently commented on ABUS. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective (up from $4.50) on shares […] - 2025-03-14 06:26:49
Comparing Arbutus Biopharma (NASDAQ:ABUS) & Akari Therapeutics (NASDAQ:AKTX): Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Akari Therapeutics (NASDAQ:AKTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Risk and Volatility Arbutus Biopharma has a […] - 2025-03-12 04:56:53
Arbutus Biopharma (NASDAQ:ABUS) Upgraded by StockNews.com to “Hold” Rating: Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a […] - 2025-03-07 04:10:47
Arbutus Biopharma (NASDAQ:ABUS) Cut to “Sell” at StockNews.com: Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of […] - 2025-02-27 04:15:04
China Universal Asset Management Co. Ltd. Buys 3,870 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS): China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,179 shares of the biopharmaceutical company’s stock after acquiring an additional 3,870 […] - 2025-02-04 06:53:07

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ABUS holdings

Date	Number of ABUS Shares Held	Base Market Value of ABUS Shares	Local Market Value of ABUS Shares	Change in ABUS Shares Held	Change in ABUS Base Value	Current Price per ABUS Share Held	Previous Price per ABUS Share Held
2025-12-16 (Tuesday)	117,289	USD 538,357	USD 538,357	0	USD -42,224	USD 4.59	USD 4.95
2025-12-15 (Monday)	117,289	USD 580,581	USD 580,581	0	USD 28,150	USD 4.95	USD 4.71
2025-12-12 (Friday)	117,289	USD 552,431	USD 552,431	0	USD 4,691	USD 4.71	USD 4.67
2025-12-11 (Thursday)	117,289	USD 547,740	USD 547,740	0	USD 9,383	USD 4.67	USD 4.59
2025-12-10 (Wednesday)	117,289	USD 538,357	USD 538,357	0	USD 15,248	USD 4.59	USD 4.46
2025-12-09 (Tuesday)	117,289	USD 523,109	USD 523,109	0	USD -7,037	USD 4.46	USD 4.52
2025-12-08 (Monday)	117,289	USD 530,146	USD 530,146	0	USD 11,729	USD 4.52	USD 4.42
2025-12-05 (Friday)	117,289	USD 518,417	USD 518,417	0	USD 1,173	USD 4.42	USD 4.41
2025-12-04 (Thursday)	117,289	USD 517,244	USD 517,244	0	USD -2,346	USD 4.41	USD 4.43
2025-12-03 (Wednesday)	117,289	USD 519,590	USD 519,590	-2,065	USD 21,884	USD 4.43	USD 4.17
2025-12-02 (Tuesday)	119,354	USD 497,706	USD 497,706	826	USD -1,297	USD 4.17	USD 4.21
2025-12-01 (Monday)	118,528	USD 499,003	USD 499,003	0	USD -23,705	USD 4.21	USD 4.41

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ABUS by Blackrock for IE00B3VWM098

Show aggregate share trades of ABUS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-03 SELL -2,065 4.450 4.110 4.144 USD -8,557 3.59 Loss of -1,136 on sale
2025-12-02 BUY 826 4.255 4.085 4.102 USD 3,388 3.59
2025-11-25 SELL -1,239 4.320 4.230 4.239 USD -5,252 3.57 Loss of -829 on sale
2025-11-24 SELL -1,239 4.420 4.185 4.208 USD -5,214 3.57 Loss of -796 on sale
2025-11-17 SELL -4,554 4.680 4.470 4.491 USD -20,452 3.54 Loss of -4,315 on sale
2025-11-12 BUY 23,274 4.870 4.630 4.654 USD 108,317 3.52
2025-11-06 SELL -335 4.600 4.350 4.375 USD -1,466 3.50 Loss of -293 on sale
2025-11-05 SELL -3,350 4.620 4.285 4.318 USD -14,467 3.49 Loss of -2,764 on sale
2025-11-04 SELL -670 4.578 4.450 4.463 USD -2,990 3.49 Loss of -654 on sale
2025-11-03 SELL -670 4.760 4.570 4.589 USD -3,075 3.48 Loss of -742 on sale
2025-10-28 BUY 1,005 4.580 4.610 4.607 USD 4,630 3.45
2025-10-24 SELL -335 4.360 4.440 4.432 USD -1,485 3.44 Loss of -333 on sale
2025-10-15 BUY 2,010 4.470 4.480 4.479 USD 9,003 3.39
2025-10-02 BUY 335 4.490 4.600 4.589 USD 1,537 3.38
2025-09-30 BUY 670 4.540 4.550 4.549 USD 3,048 3.36
2025-08-21 SELL -335 3.580 3.580 3.580 USD -1,199 3.33 Loss of -83 on sale
2025-07-31 BUY 1,002 3.280 3.370 3.361 USD 3,368 3.33
2025-06-30 SELL -670 3.090 3.120 3.117 USD -2,088 3.35 Profit of 158 on sale
2025-06-25 SELL -335 3.340 3.400 3.394 USD -1,137 3.36 Loss of -13 on sale
2025-06-20 SELL -670 3.430 3.540 3.529 USD -2,364 3.35 Loss of -117 on sale
2025-05-23 BUY 335 3.220 3.240 3.238 USD 1,085 3.34
2025-05-19 SELL -335 3.130 3.160 3.157 USD -1,058 3.34 Profit of 62 on sale
2025-05-15 SELL -1,005 3.120 3.150 3.147 USD -3,163 3.35 Profit of 202 on sale
2025-05-12 SELL -335 3.350 3.370 3.368 USD -1,128 3.35 Loss of -5 on sale
2025-05-09 SELL -335 3.230 3.370 3.356 USD -1,124 3.35 Loss of -1 on sale
2025-04-30 SELL -335 3.550 3.620 3.613 USD -1,210 3.35 Loss of -90 on sale
2025-04-24 SELL -670 3.340 3.350 3.349 USD -2,244 3.35 Loss of -3 on sale
2025-04-17 SELL -335 3.150 3.160 3.159 USD -1,058 3.36 Profit of 66 on sale
2025-04-15 SELL -1,005 3.160 3.340 3.322 USD -3,339 3.36 Profit of 41 on sale
2025-04-14 SELL -1,005 3.280 3.310 3.307 USD -3,324 3.36 Profit of 58 on sale
2025-04-09 SELL -1,340 3.170 3.230 3.224 USD -4,320 3.37 Profit of 202 on sale
2025-04-07 SELL -2,345 3.010 3.140 3.127 USD -7,333 3.39 Profit of 613 on sale
2025-04-04 SELL -3,360 3.230 3.460 3.437 USD -11,548 3.39 Loss of -155 on sale
2025-03-31 BUY 336 3.490 3.540 3.535 USD 1,188 3.39
2025-03-19 SELL -672 3.310 3.320 3.319 USD -2,230 3.39 Profit of 49 on sale
2025-03-17 BUY 29,976 3.280 3.310 3.307 USD 99,131 3.40
2025-03-14 SELL -1,464 3.300 3.410 3.399 USD -4,976 3.40 Profit of 1 on sale
2025-03-13 SELL -490 3.320 3.510 3.491 USD -1,711 3.40 Loss of -44 on sale
2025-03-12 SELL -8,330 3.190 3.200 3.199 USD -26,648 3.41 Profit of 1,727 on sale
2025-03-07 SELL -490 3.310 3.420 3.409 USD -1,670 3.42 Profit of 7 on sale
2025-03-06 SELL -735 3.370 3.550 3.532 USD -2,596 3.42 Loss of -79 on sale
2025-03-04 BUY 34,868 3.390 3.570 3.552 USD 123,851 3.42
2025-03-03 SELL -151 3.420 3.520 3.510 USD -530 3.42 Loss of -13 on sale
2025-02-28 SELL -36,642 3.450 3.490 3.486 USD -127,734 3.42 Loss of -2,264 on sale
2025-02-26 SELL -246 3.440 3.560 3.548 USD -873 3.43 Loss of -30 on sale
2025-02-25 SELL -738 3.450 3.700 3.675 USD -2,712 3.42 Loss of -185 on sale
2025-02-18 BUY 1,230 3.360 3.440 3.432 USD 4,221 3.43
2025-02-13 BUY 246 3.300 3.360 3.354 USD 825 3.45
2025-02-12 BUY 246 3.310 3.320 3.319 USD 816 3.45
2025-02-11 BUY 738 3.310 3.340 3.337 USD 2,463 3.46
2025-02-06 BUY 2,205 3.410 3.620 3.599 USD 7,936 3.47
2025-01-27 BUY 245 3.430 3.450 3.448 USD 845 3.53
2024-12-06 BUY 980 3.680 3.730 3.725 USD 3,651 3.51
2024-12-05 BUY 245 3.630 3.790 3.774 USD 925 3.49
2024-12-04 BUY 1,225 3.740 3.750 3.749 USD 4,593 3.45
2024-11-29 BUY 1,225 3.460 3.510 3.505 USD 4,294 3.45
2024-11-27 BUY 980 3.470 3.500 3.497 USD 3,427 3.41
2024-11-26 BUY 245 3.410 3.470 3.464 USD 849 0.00
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-03	SELL	-2,065	4.450	4.110	4.144	USD -8,557	3.59 Loss of -1,136 on sale
2025-12-02	BUY	826	4.255	4.085	4.102	USD 3,388	3.59
2025-11-25	SELL	-1,239	4.320	4.230	4.239	USD -5,252	3.57 Loss of -829 on sale
2025-11-24	SELL	-1,239	4.420	4.185	4.208	USD -5,214	3.57 Loss of -796 on sale
2025-11-17	SELL	-4,554	4.680	4.470	4.491	USD -20,452	3.54 Loss of -4,315 on sale
2025-11-12	BUY	23,274	4.870	4.630	4.654	USD 108,317	3.52
2025-11-06	SELL	-335	4.600	4.350	4.375	USD -1,466	3.50 Loss of -293 on sale
2025-11-05	SELL	-3,350	4.620	4.285	4.318	USD -14,467	3.49 Loss of -2,764 on sale
2025-11-04	SELL	-670	4.578	4.450	4.463	USD -2,990	3.49 Loss of -654 on sale
2025-11-03	SELL	-670	4.760	4.570	4.589	USD -3,075	3.48 Loss of -742 on sale
2025-10-28	BUY	1,005	4.580	4.610	4.607	USD 4,630	3.45
2025-10-24	SELL	-335	4.360	4.440	4.432	USD -1,485	3.44 Loss of -333 on sale
2025-10-15	BUY	2,010	4.470	4.480	4.479	USD 9,003	3.39
2025-10-02	BUY	335	4.490	4.600	4.589	USD 1,537	3.38
2025-09-30	BUY	670	4.540	4.550	4.549	USD 3,048	3.36
2025-08-21	SELL	-335	3.580	3.580	3.580	USD -1,199	3.33 Loss of -83 on sale
2025-07-31	BUY	1,002	3.280	3.370	3.361	USD 3,368	3.33
2025-06-30	SELL	-670	3.090	3.120	3.117	USD -2,088	3.35 Profit of 158 on sale
2025-06-25	SELL	-335	3.340	3.400	3.394	USD -1,137	3.36 Loss of -13 on sale
2025-06-20	SELL	-670	3.430	3.540	3.529	USD -2,364	3.35 Loss of -117 on sale
2025-05-23	BUY	335	3.220	3.240	3.238	USD 1,085	3.34
2025-05-19	SELL	-335	3.130	3.160	3.157	USD -1,058	3.34 Profit of 62 on sale
2025-05-15	SELL	-1,005	3.120	3.150	3.147	USD -3,163	3.35 Profit of 202 on sale
2025-05-12	SELL	-335	3.350	3.370	3.368	USD -1,128	3.35 Loss of -5 on sale
2025-05-09	SELL	-335	3.230	3.370	3.356	USD -1,124	3.35 Loss of -1 on sale
2025-04-30	SELL	-335	3.550	3.620	3.613	USD -1,210	3.35 Loss of -90 on sale
2025-04-24	SELL	-670	3.340	3.350	3.349	USD -2,244	3.35 Loss of -3 on sale
2025-04-17	SELL	-335	3.150	3.160	3.159	USD -1,058	3.36 Profit of 66 on sale
2025-04-15	SELL	-1,005	3.160	3.340	3.322	USD -3,339	3.36 Profit of 41 on sale
2025-04-14	SELL	-1,005	3.280	3.310	3.307	USD -3,324	3.36 Profit of 58 on sale
2025-04-09	SELL	-1,340	3.170	3.230	3.224	USD -4,320	3.37 Profit of 202 on sale
2025-04-07	SELL	-2,345	3.010	3.140	3.127	USD -7,333	3.39 Profit of 613 on sale
2025-04-04	SELL	-3,360	3.230	3.460	3.437	USD -11,548	3.39 Loss of -155 on sale
2025-03-31	BUY	336	3.490	3.540	3.535	USD 1,188	3.39
2025-03-19	SELL	-672	3.310	3.320	3.319	USD -2,230	3.39 Profit of 49 on sale
2025-03-17	BUY	29,976	3.280	3.310	3.307	USD 99,131	3.40
2025-03-14	SELL	-1,464	3.300	3.410	3.399	USD -4,976	3.40 Profit of 1 on sale
2025-03-13	SELL	-490	3.320	3.510	3.491	USD -1,711	3.40 Loss of -44 on sale
2025-03-12	SELL	-8,330	3.190	3.200	3.199	USD -26,648	3.41 Profit of 1,727 on sale
2025-03-07	SELL	-490	3.310	3.420	3.409	USD -1,670	3.42 Profit of 7 on sale
2025-03-06	SELL	-735	3.370	3.550	3.532	USD -2,596	3.42 Loss of -79 on sale
2025-03-04	BUY	34,868	3.390	3.570	3.552	USD 123,851	3.42
2025-03-03	SELL	-151	3.420	3.520	3.510	USD -530	3.42 Loss of -13 on sale
2025-02-28	SELL	-36,642	3.450	3.490	3.486	USD -127,734	3.42 Loss of -2,264 on sale
2025-02-26	SELL	-246	3.440	3.560	3.548	USD -873	3.43 Loss of -30 on sale
2025-02-25	SELL	-738	3.450	3.700	3.675	USD -2,712	3.42 Loss of -185 on sale
2025-02-18	BUY	1,230	3.360	3.440	3.432	USD 4,221	3.43
2025-02-13	BUY	246	3.300	3.360	3.354	USD 825	3.45
2025-02-12	BUY	246	3.310	3.320	3.319	USD 816	3.45
2025-02-11	BUY	738	3.310	3.340	3.337	USD 2,463	3.46
2025-02-06	BUY	2,205	3.410	3.620	3.599	USD 7,936	3.47
2025-01-27	BUY	245	3.430	3.450	3.448	USD 845	3.53
2024-12-06	BUY	980	3.680	3.730	3.725	USD 3,651	3.51
2024-12-05	BUY	245	3.630	3.790	3.774	USD 925	3.49
2024-12-04	BUY	1,225	3.740	3.750	3.749	USD 4,593	3.45
2024-11-29	BUY	1,225	3.460	3.510	3.505	USD 4,294	3.45
2024-11-27	BUY	980	3.470	3.500	3.497	USD 3,427	3.41
2024-11-26	BUY	245	3.410	3.470	3.464	USD 849	0.00

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ABUS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE